Inogen, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2025

activity for the three months ended March 31, 2025 is summarized below:


										Weighted-
										average
										grant
				Performance						date fair
				and						value
Restricted stock units	Time-based			time-based			Total			per share
Unvested restricted stock units as of December 31, 2024		1,203,383			601,194			1,804,577		$	8.61
Granted		700,630			822,308			1,522,938			9.84
Vested		(241,355	)		(118,100	)		(359,455	)		10.43
Forfeited/canceled		(41,175	)		(82,213	)		(123,388	)		10.41
Unvested restricted stock units as of March 31, 2025 (1)		1,621,483			1,223,189			2,844,672		$	8.86
Unvested and expected to vest restricted stock units outstanding as of March 31, 2025								1,937,480		$	8.83

(1) Outstanding RSUs are based on the maximum payout of the targeted number of shares.

Summary of Stock-based Compensation Expense

Stock-based compensation expense recognized for the three months ended March 31, 2025 and 2024, was as follows:


	Three months ended
	March 31,
	2025		2024
Stock-based compensation expense by type of award:
Restricted stock units	$	2,008	$	2,309
Employee stock purchase plan		139		107
Total stock-based compensation expense	$	2,147	$	2,416

For the three months ended March 31, 2025 and 2024, respectively, stock-based compensation expense recognized under ASC 718, included in cost of revenue, research and development expense, sales and marketing expense, and general and administrative expense was as follows:


	Three months ended
	March 31,
	2025		2024
Cost of revenue	$	167	$	180
Research and development		95		460
Sales and marketing		214		430
General and administrative		1,671		1,346
Total stock-based compensation expense	$	2,147	$	2,416